Adults 18 to 30, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Change in Proportion of Days With Pain Due to Sickle Cell Disease as Measured by an eDiaryPrimary· Baseline through Week 12
To investigate the efficacy of 2 different doses of ticagrelor versus placebo in reducing the number of days with pain due to sickle cell disease.
Group
Value
95% CI
PLACEBO 10MG BID + PLACEBO 45MG BID
-0.1802
-0.2673 – -0.0931
TICAGRELOR 10MG BID + PLACEBO 45MG BID
-0.1352
-0.2260 – -0.0444
TICAGRELOR 45MG BID + PLACEBO 10MG BID
-0.1001
-0.1881 – -0.0121
Average of the Daily Worst Pain Values Reported Via eDiarySecondary· Baseline through Week 12
To determine the efficacy of 2 different doses of ticagrelor versus placebo in reducing the intensity of pain due to sickle cell disease. Intensity of pain was recorded on an 11-point scale where 0 represented no pain and 10 represented the worst pain imaginable.
Group
Value
95% CI
PLACEBO 10MG BID + PLACEBO 45MG BID
1.02
± 1.106
TICAGRELOR 10MG BID + PLACEBO 45MG BID
1.15
± 1.547
TICAGRELOR 45MG BID + PLACEBO 10MG BID
1.74
± 2.277
Change in Proportion of Days With Analgesic Use Measured by an eDiarySecondary· Baseline through Week 12
To assess the efficacy of 2 different doses of ticagrelor versus placebo in reducing the use of analgesics by patients with sickle cell disease.
Group
Value
95% CI
PLACEBO 10MG BID + PLACEBO 45MG BID
-0.1991
-0.2753 – -0.1230
TICAGRELOR 10MG BID + PLACEBO 45MG BID
-0.0799
-0.1590 – -0.0008
TICAGRELOR 45MG BID + PLACEBO 10MG BID
-0.1016
-0.1782 – -0.0250
Number of Major Bleeding or Clinically Relevant Non-major Bleeding Events (Patients)Secondary· Baseline through Week 12
To assess safety and tolerability of 2 different doses of ticagrelor versus placebo in patients with SCD
Patients with any bleeding events
Group
Value
95% CI
PLACEBO 10MG BID + PLACEBO 45MG BID
2
TICAGRELOR 10MG BID + PLACEBO 45MG BID
2
TICAGRELOR 45MG BID + PLACEBO 10MG BID
2
Pts w/ any bleeding event requiring intervention
Group
Value
95% CI
PLACEBO 10MG BID + PLACEBO 45MG BID
2
TICAGRELOR 10MG BID + PLACEBO 45MG BID
1
TICAGRELOR 45MG BID + PLACEBO 10MG BID
2
Number of Major Bleeding or Clinically Relevant Non-major Bleeding Events (Events)Secondary· Baseline through Week 12
To assess safety and tolerability of 2 different doses of ticagrelor versus placebo in patients with SCD
Total number of bleeding events
Group
Value
95% CI
PLACEBO 10MG BID + PLACEBO 45MG BID
2
TICAGRELOR 10MG BID + PLACEBO 45MG BID
2
TICAGRELOR 45MG BID + PLACEBO 10MG BID
2
Maximum severity of bleeding event: Minor
Group
Value
95% CI
PLACEBO 10MG BID + PLACEBO 45MG BID
0
TICAGRELOR 10MG BID + PLACEBO 45MG BID
1
TICAGRELOR 45MG BID + PLACEBO 10MG BID
0
Max sever. of bleed event: Clin-relevant nonmajor
Group
Value
95% CI
PLACEBO 10MG BID + PLACEBO 45MG BID
2
TICAGRELOR 10MG BID + PLACEBO 45MG BID
1
TICAGRELOR 45MG BID + PLACEBO 10MG BID
2
Maximum severity of bleeding event: Major
Group
Value
95% CI
PLACEBO 10MG BID + PLACEBO 45MG BID
0
TICAGRELOR 10MG BID + PLACEBO 45MG BID
0
TICAGRELOR 45MG BID + PLACEBO 10MG BID
0
Adverse events — posted to ClinicalTrials.gov
Reporting threshold: 5%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The purpose of this study is to determine whether ticagrelor is effective in reducing the number of days of pain, intensity of pain, and reducing the use of analgesics due to sickle cell disease
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
NCT06451198 — IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
· Phase 4
· recruiting
NCT07358416 — Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
· active not recruiting
NCT06584812 — Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects
· Phase 1
· completed
NCT06554821 — A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy
· Phase 1
· completed
NCT06301776 — A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy
· NA
· recruiting
Other recruiting trials for Sickle Cell Disease
Currently open trials in the same condition.
NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
· Phase 2
· recruiting
NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease
· Phase 2
· recruiting
NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
· Phase 2
· recruiting
NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease
· NA
· recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
· Phase 2
· recruiting
Other AstraZeneca trials
Trials by the same sponsor.
NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea
· not yet recruiting
NCT07431775 — Saphnelo Use in Females of Child-bearing Potential
· not yet recruiting
NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis
· NA
· not yet recruiting
NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec
· Phase 4
· not yet recruiting
NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
Last refreshed: 19 December 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02482298.